Visceral adipose tissue accumulation, secretory phospholipase A2-IIA and atherogenecity of LDL.
OBJECTIVE
The aim of the present study was to investigate the combined impact of visceral adipose tissue (VAT) and secretory group IIA phospholipase A(2) (sPLA(2)-IIA) concentrations on the atherogenicity of low-density lipoprotein (LDL) particles among men.


METHODS
Analyses were conducted in 74 mid-obese healthy men (age: (mean+/-s.d.) 37.9+/-11.7 years).


METHODS
Plasma levels of sPLA(2)-IIA were measured with a commercial ELISA and VAT levels were assessed by computed tomography. Distinct subpopulations of LDL particles were characterized from whole plasma using nondenaturating 2-16% gradient gel electrophoresis.


RESULTS
Data indicated that plasma sPLA(2)-IIA levels were approximately 29% (P=0.007) higher among men characterized by a higher accumulation of VAT (>142 vs < or =142 cm(2)). Men having high plasma sPLA(2)-IIA levels (> or =127.2 ng/dl, the median value), were characterized by higher levels of plasma cholesterol (C) and apolipoprotein (apo) B, LDL-C, LDL-apoB, oxidized LDL (OxLDL) and by smaller LDL particles compared to men with sPLA(2)-IIA<127.2 ng/dl. Multiple regression analyses showed that plasma triglycerides and sPLA(2)-IIA levels explained 22.7 and 11.8% of the variance in LDL peak particle size, respectively. Levels of VAT and of sPLA(2)-IIA were the strongest correlates of OxLDL levels explaining, respectively, 15.0 and 5.5% of their variability.


CONCLUSIONS
Both VAT and sPLA(2)-IIA levels modulate the atherogenecity of LDL by accounting for the reduction in their size and their susceptibility to oxidation.
Paradis
M-E
ME
Institute on Nutraceuticals and Functional Foods, Laval University, Québec, Canada.
Hogue
M-O
MO
Mauger
J-F
JF
Couillard
C
C
Couture
P
P
Bergeron
N
N
Lamarche
B
B
D000328:Adult; D001055:Apolipoproteins B / Q000097:blood; D050197:Atherosclerosis / Q000097:blood / Q000209:etiology*; D002784:Cholesterol / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D054501:Group II Phospholipases A2; D006801:Humans; D015850:Interleukin-6 / Q000097:blood; D050152:Intra-Abdominal Fat / Q000473:pathology* / Q000503:physiopathology; D008077:Lipoproteins, LDL / Q000097:blood*; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000097:blood* / Q000150:complications / Q000503:physiopathology; D010084:Oxidation-Reduction; D010741:Phospholipases A / Q000097:blood*; D054467:Phospholipases A2; D012044:Regression Analysis; D012307:Risk Factors; D014280:Triglycerides / Q000097:blood
D001055:Apolipoproteins B; D008078:Cholesterol, LDL; D015850:Interleukin-6; D008077:Lipoproteins, LDL; D014280:Triglycerides; D002784:Cholesterol; D010741:Phospholipases A; D054501:Group II Phospholipases A2; D054467:Phospholipases A2